The Ministry of Science and Technology has recently issued some state-level science and technology projects in 2007. Changzhou Niutang Chemical Factory Co., Ltd. has included sucralose key technology integration innovation and its industrialization, and hydroxybenzene ethanol project. The former was included in the National Torch Plan, and the latter was included in the national key new product plan, and was funded by the central government's research and development fund of 300,000 yuan.
Sucralose is the only sugar substitute that is consistent with sucrose and suitable for most people's tastes. The sweetness of the product is 650 times that of sucrose, and the calories are 0. It does not participate in human metabolism and is resistant to high temperatures. The sucralose project is planned to form a 600 tons/year production scale in 2010, and the sales revenue is expected to reach 900 million yuan.
p-Hydroxyphenethyl alcohol is a key intermediate for a new class of drugs such as metoprolol and betaxolol. Metoprolol and betallol are among the first choices for treating hypertension. The project will integrate and innovate the key key technologies in the synthesis of p-hydroxyphenylethanol to form a 300-ton/year production scale of p-hydroxyphenylethanol.
Both projects have independent intellectual property rights. The sucralose project applied for 7 invention patents, including 1 US invention patent and 2 authorizations. The p-hydroxyphenyl ethanol project has one authorized invention patent.
Sucralose is the only sugar substitute that is consistent with sucrose and suitable for most people's tastes. The sweetness of the product is 650 times that of sucrose, and the calories are 0. It does not participate in human metabolism and is resistant to high temperatures. The sucralose project is planned to form a 600 tons/year production scale in 2010, and the sales revenue is expected to reach 900 million yuan.
p-Hydroxyphenethyl alcohol is a key intermediate for a new class of drugs such as metoprolol and betaxolol. Metoprolol and betallol are among the first choices for treating hypertension. The project will integrate and innovate the key key technologies in the synthesis of p-hydroxyphenylethanol to form a 300-ton/year production scale of p-hydroxyphenylethanol.
Both projects have independent intellectual property rights. The sucralose project applied for 7 invention patents, including 1 US invention patent and 2 authorizations. The p-hydroxyphenyl ethanol project has one authorized invention patent.